CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Clade Therapeutics
Main focus: Novel stem cell-derived cellular therapies
Company stage: Pre-clinical
Diseases: Undisclosed
Genome editing tool: Undisclosed
Funding stage: Private
Location: Cambridge, MA, USA
Website: https://cladetx.com/
Clade Therapeutics is focused on the development of next-generation cellular therapies, applying its induced pluripotent stem cell (iPSC)-based platform. Using its technology, it is able to generate iPSC-derived adult T, natural killer (NK) and B cells. The company is co-founded by Chad Cowan, a CRISPR Therapeutics co-founder, however, exactly how gene editing is used in the cell therapies under development has not yet been undisclosed.
